Nano-particle dynamics during capillary suction.

Due to the increased use of nanoparticles in everyday applications, there is a need for theoretical descriptions of particle transport and attachment in porous media. It should be possible to develop a one dimensional model to describe nanoparticle retention during capillary transport of liquid mixtures in porous media. Water-glycerol-nanoparticle mixtures were prepared and the penetration process in porous Al2O3 samples of varying pore size is measured using NMR imaging. The liquid and particle front can be measured by utilizing T2 relaxation effects from the paramagnetic nanoparticles. A good agreement between experimental data and the predicted particle retention by the developed theory is found. Using the model, the binding constant for Fe2O3 nanoparticles on sintered Al2O3 samples and the maximum surface coverage are determined. Furthermore, we show that the penetrating liquid front follows a square root of time behavior as predicted by Darcy's law. However, scaling with the liquid parameters is no longer sufficient to map different liquid mixtures onto a single master curve. The Darcy model should be extended to address the two formed domains (with and without particles) and their interaction, to give an accurate prediction for the penetrating liquid front.

CDK4/6 inhibition in early and metastatic breast cancer: A review.

Breast cancer (BC) is responsible for 14% of cancer-related deaths in women [1]. Cyclin-dependent kinase (CDK) 4/6 inhibitors are a new class of selective drugs, offering an effective and tolerable treatment. CDK4/6 inhibitors induce cell cycle arrest in the G1 phase, and may thereby prevent tumour progression. Three CDK4/6 inhibitors have been tested in clinical BC trials: palbociclib, ribociclib, and abemaciclib. The Food and Drug Administration (FDA) and European Commission (EMA) have approved palbociclib for the treatment of patients HR+ HER2- locally advanced or metastatic BC (aBC) in combination with an aromatase inhibitor as initial therapy in postmenopausal women or in combination with fulvestrant in women who have received prior endocrine therapy. Ribociclib has been approved by the FDA in combination with an aromatase inhibitor as initial therapy for postmenopausal women with HR+ HER2- aBC. Moreover, CDK4/6 inhibitors have shown promising results in the (neo)adjuvant setting. In this review, the principal completed and ongoing clinical trials in aBC are reviewed for both the metastatic as (neo)adjuvant setting. Tables will provide a complete overview of the ongoing clinical trials. At last, the future perspectives of these CDK4/6 inhibitors are discussed.